MDGL
Madrigal Pharmaceuticals, Inc.
212.35
USD
This page is just a preview of the data found in TrendSpider’s full version
Madrigal Pharmaceuticals, Inc. stock is up 44.56% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.82% of the previous 16 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 30 Nov 18:32 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:46 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:49 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:49 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:50 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:51 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:51 | 17 Jan, 2025 | 200.00 | 80 | ||
| 30 Nov 20:51 | 17 Jan, 2025 | 200.00 | 80 | ||
| 01 Dec 20:21 | 19 Jan, 2024 | 175.00 | 167 | ||
| 01 Dec 20:42 | 19 Apr, 2024 | 250.00 | 297 |
Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.
